Search

everythinglearnresearchcommunity

for

Search:↓

A compound called MTP3 from the Monoterpene family was found to be safe and highly effective at treating hair loss by inhibiting the FGF5 gene, but its identity is undisclosed for commercial reasons. No specific treatments like Minoxidil, finasteride, or RU58841 were discussed.

A user is quitting ketoconazole shampoo, believing it worsened their hair condition, and plans to use clarifying, keratin, and pH balanced moisturizing shampoos instead. Another user suggests using conditioner after ketoconazole to prevent dryness.

PP405 and hair cloning are discussed as potential treatments for reversing hair loss from Norwood 7 to Norwood 1. Hair cloning is seen as a more permanent solution, while PP405's effectiveness and long-term effects remain uncertain.

Using 2% ketoconazole daily can dry out the scalp; 1-2 times a week is recommended. Combining ketoconazole with treatments like minoxidil, alfatradiol, and fluridil can help manage hair loss effectively.

The conversation is about the effectiveness of peptides for hair loss and the user considering using GHK-Cu, CJC-1295, and BPC-157 for treatment.

The user is considering starting minoxidil and finasteride for hair loss at Norwood 2 or 2.5. Another user suggests consulting a dermatologist and possibly using finasteride to prevent progression and minoxidil for regrowth, with dutasteride as an alternative.

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

The conversation discusses making a GHK-CU and AHK-CU serum for hair loss. A user shared that they tried both but found them ineffective.

User seeks availability of Breezula and its delayed trials. Asks for success with similar topical antiandrogens like fluridil.

HairClone aims to rejuvenate miniaturizing hair follicles through follicle banking and cell expansion, with treatments potentially available in the UK by 2022. The process involves extracting, storing, and cloning hair follicles, but full regenerative treatments will take many years to develop.

The conversation is about hair loss treatments, specifically the anticipation for the release of a new treatment, GT20029, by 2028. Users are discussing their experiences with current treatments like finasteride and dutasteride, and the potential of future treatments, including FAK inhibitors and verteporfin trials.

The conversation is about when GT20029, a hair loss treatment, might be available on the grey market, with users discussing the challenges of compounding it and speculating it might be available after phase 2 results, similar to pyri. Specific treatments mentioned are pyri, RU58841, and GT20029.

Hair loss treatments RU55841, CB-03-01, and Eucapil were discussed, with concerns about needing increased dosages over time and potential side effects. A user suggested that CB's results could be due to various factors and that combining it with finasteride might slow down any upregulation.

The user reports slight progress in hair growth after 3.5 months of using Kirkland Minoxidil twice daily and finasteride once daily, along with biotin and nioxin shampoo. They are pleased with the results and have experienced no side effects.

GHK-RU58841 is used for hair loss, with positive results when combined with finasteride, stemoxydine, redensyl, and alfatradiol. Users report effectiveness after adding finasteride.

Kintor Pyrilutamide treatment, a potential hair loss treatment that may become available to the public soon. People have been experimenting with using it in topical form, with mixed results and no reported side effects.

ET-02 (RS 5441) shows promising results for hair growth, performing better in humans than in mice. There is debate over the effectiveness compared to minoxidil, with some users wanting more detailed data.

GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.

Kintor's 1% Pyrilutamide will be released in October/November. The user cannot tolerate finasteride.

Pyrilutamide (KX-826) is being discussed as a potential hair loss treatment, with some users reporting no regrowth after three months. It may prevent further hair loss but might not promote regrowth unless combined with Minoxidil.

The conversation discusses using GHK-Cu, C60, and saw palmetto oil as treatments for hair loss. Specific treatments mentioned include Minoxidil (Min), Finasteride (Fin), and RU58841 (RU).

A new hair loss treatment, KX-826, is being discussed as a stronger and safer alternative to RU58841 and finasteride. Opinions are mixed, with some users skeptical about its effectiveness and others considering it as part of their regimen.

PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hair follicle stem cells to reactivate growth, while GT20029 works as an androgen receptor deleter, both requiring ongoing use for effectiveness.

The conversation is about purchasing Cb-03-01 for research purposes. The user seeks advice on where and how to buy it outside the U.S.

Hair loss discussion includes treatments like hinoki tree oil and procyanidin b2. Experiences and effectiveness of these treatments are shared.

Oral minoxidil may require potassium for effectiveness, and diuretics taken for water retention might affect this process. The user plans to start taking potassium to address potential issues with minoxidil's effectiveness.

A user is exploring VEGF gene therapy to enhance hair transplant results, considering measuring hair shaft diameter and growth rate. Suggestions include using phototrichograms and possibly adding PRP, though its effectiveness is uncertain.

GT20029 and CosmeRNA are both potential hair loss treatments; GT20029 breaks down the androgen receptor, while CosmeRNA prevents its production. Continuous use is needed, but less frequently than current treatments like Minoxidil and Finasteride.

A user shared progress pictures showing improvement from NW 6 to NW 2 after four months of treatment. They are considering using exosomes to further reverse hair miniaturization.

The conversation is about the approval of Clascoterone (Winlevi) in Canada for hair loss treatment. One user expressed skepticism about its effectiveness due to low concentration.